Repurposed asthma drug reverses diabetes in mouse study

02/11/2013 | Genetic Engineering & Biotechnology News

Amlexanox, an off-patent asthma drug, reversed obesity, diabetes and fatty liver disease in mice, according to a study published in Nature Medicine. The drug appears to inhibit the IKK(epsilon) and TBK1 genes, which might allow the metabolic system to burn more energy, University of Michigan Life Sciences Institute researcher Alan Saltiel said. Researchers plan to test the drug in clinical trials and are working on optimized formulas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID